Company Overview

Adagio Medical Holdings, Inc. is a clinical-stage medical technology company focused on the development of catheter-based cryoablation technologies for the treatment of cardiac arrhythmias, primarily ventricular tachycardia (VT) and atrial fibrillation (AF). The company operates within the cardiac electrophysiology and interventional cardiology industries, addressing conditions associated with high morbidity, mortality, and healthcare costs.

The company’s core product candidates are based on proprietary near-critical nitrogen cryoablation technology, designed to create deeper, more durable cardiac lesions than conventional ablation systems. Adagio’s strategy targets patients with complex arrhythmias who are underserved by existing therapies. The company was founded in 2011 and went public in 2021 through a merger with a special purpose acquisition company, subsequently listing on Nasdaq under the ticker ADGM. Since inception, Adagio has remained pre-commercial, focusing on clinical trials, regulatory approvals, and technology validation.

Business Operations

Adagio operates as a single operating segment focused on the research, development, and clinical validation of its cryoablation platform. Its primary product candidates include the vCLAS™ Cryoablation System for VT and the AFCLAS™ Cryoablation System for AF, both of which integrate proprietary catheters, consoles, and disposable components intended for use in hospital electrophysiology labs.

Operations are primarily centered on research and development, clinical trials, regulatory affairs, and manufacturing oversight, with no material commercial revenue as of the most recent public filings. Clinical activities are conducted in collaboration with hospitals, investigators, and research institutions in the United States and select international markets. Manufacturing is supported through a combination of internal capabilities and third-party suppliers, while commercialization infrastructure remains limited pending regulatory approvals.

Strategic Position & Investments

Adagio’s strategic focus is on advancing its cryoablation systems through late-stage clinical trials and obtaining regulatory approvals, particularly from the U.S. Food and Drug Administration. The company positions its technology as a potential alternative to radiofrequency ablation by emphasizing deeper lesion formation, procedural efficiency, and improved durability in complex arrhythmia cases.

Investment priorities have centered on internal product development rather than acquisitions, with capital allocated toward clinical studies, engineering enhancements, and intellectual property protection. Adagio does not report material investments in external portfolio companies, and its strategy emphasizes organic growth driven by technological differentiation. Emerging focus areas include expanded indications for VT and AF treatment and potential applications of its cryogenic platform in additional cardiac use cases.

Geographic Footprint

Adagio Medical Holdings is headquartered in the United States, with principal executive offices and research operations located in California. The company’s clinical trial footprint extends across North America and Europe, reflecting its focus on regulatory pathways in major developed healthcare markets.

While commercial operations are not yet established, Adagio maintains international relationships with clinical investigators and regulatory bodies, supporting its long-term objective of global market entry. Its geographic influence is currently driven more by clinical and regulatory activity than by sales or distribution infrastructure.

Leadership & Governance

Adagio is led by executives with backgrounds in medical devices, electrophysiology, and healthcare innovation. The leadership team emphasizes disciplined clinical execution, regulatory rigor, and long-term value creation through differentiated technology.

• Olav Bergheim – President and Chief Executive Officer
• Todd Usen – Chief Financial Officer (Data inconclusive based on available public sources regarding tenure continuity)
• Amit Vasanji, M.D. – Chief Medical Officer
• Peter Thorpe – Chief Technology Officer (Data inconclusive based on available public sources)

The board and management team collectively articulate a strategy centered on addressing unmet needs in complex arrhythmia care, prioritizing patient outcomes, and building sustainable clinical evidence prior to commercialization.